Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Giusti

Showing results (71-80 of 138) with videos related to

Pageof 14
Sort By:
Pharmacoeconomics - Open|March 4, 2021
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?Giancarlo Pruneri, Filippo De Braud, Anna Sapino, et al.
Frontiers in Oncology|April 17, 2026
Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journalsRaffaele Giusti, Marco Filetti, Pasquale Lombardi, et al.
ESMO Open|April 2, 2020
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspectiveMatteo Lambertini, Angela Toss, Antonio Passaro, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 2, 2019
What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudesAlessio Cortellini, Giampiero Porzio, Vincenza Cofini, et al.
Frontiers in Immunology|August 1, 2020
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1Andrea Botticelli, Silvia Mezi, Giulia Pomati, et al.
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
Journal of Translational Medicine|March 29, 2019
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumabAndrea Botticelli, Massimiliano Salati, Francesca Romana Di Pietro, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2015
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysisRita Chiari, Giulio Metro, Daniela Iacono, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2024
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-AnalysisDaniele Marinelli, Antonio Nuccio, Alessandro Di Federico, et al.
Pageof 14

Showing results (71-80 of 138) with videos related to

Sort By:
Pageof 14
Pharmacoeconomics - Open|March 4, 2021
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?Giancarlo Pruneri, Filippo De Braud, Anna Sapino, et al.
Frontiers in Oncology|April 17, 2026
Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journalsRaffaele Giusti, Marco Filetti, Pasquale Lombardi, et al.
ESMO Open|April 2, 2020
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspectiveMatteo Lambertini, Angela Toss, Antonio Passaro, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 2, 2019
What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudesAlessio Cortellini, Giampiero Porzio, Vincenza Cofini, et al.
Frontiers in Immunology|August 1, 2020
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1Andrea Botticelli, Silvia Mezi, Giulia Pomati, et al.
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
Journal of Translational Medicine|March 29, 2019
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumabAndrea Botticelli, Massimiliano Salati, Francesca Romana Di Pietro, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2015
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysisRita Chiari, Giulio Metro, Daniela Iacono, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2024
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-AnalysisDaniele Marinelli, Antonio Nuccio, Alessandro Di Federico, et al.
Pageof 14